Nivolumab and hyaluronidase (NIVO + HYAL) for subcutaneous (SC) administration: A review of efficacy and safety results from CheckMate 67T.
This program is not CME accredited.
This event has ended.
Thank you to those who were able to join us.
- January 16, 2025
- 6:30 PM EST - 7:30 PM EST
- 1 Hour
